The most common conditions that are the largest cost centers in the U.S
Type 2 Diabetes Research HbA1c reductions up to 2.02% were observed in phase 2 trials, exceeding placebo and comparator arms, with concurrent weight loss
Liraglutide 3 mg (Saxenda): A GLP-1 receptor agonist licensed for weight management
In clinical trials [2], the most common side effects were mild digestive issues, including: nausea diarrhoea vomiting constipation These symptoms were dose-related, usually mild to moderate, and often improved when the dose was increased more slowly
In addition to its insulinotropic effect, GLP-1 also act in concert with PYY and OXM to induce satiety (Figure 1)
When to seek urgent medical attention: Contact your trial team or seek urgent care (via 999 or A&E) if you experience severe or persistent abdominal pain (which may indicate pancreatitis or gallbladder disease), persistent vomiting, signs of dehydration (such as dizziness, reduced urine output, or extreme thirst), or any signs of an allergic reaction (such as rash, swelling, or difficulty breathing)